FR2707011A1 - Immunological process for the detection and assay of antibodies directed against poly(ADP-ribose) polymerase, application to diagnosis, kit for its implementation - Google Patents
Immunological process for the detection and assay of antibodies directed against poly(ADP-ribose) polymerase, application to diagnosis, kit for its implementation Download PDFInfo
- Publication number
- FR2707011A1 FR2707011A1 FR9307792A FR9307792A FR2707011A1 FR 2707011 A1 FR2707011 A1 FR 2707011A1 FR 9307792 A FR9307792 A FR 9307792A FR 9307792 A FR9307792 A FR 9307792A FR 2707011 A1 FR2707011 A1 FR 2707011A1
- Authority
- FR
- France
- Prior art keywords
- polymerase
- adp
- ribose
- directed against
- antibodies directed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 title claims abstract description 13
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title claims abstract description 13
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title claims abstract description 12
- 238000001514 detection method Methods 0.000 title abstract description 4
- 238000003745 diagnosis Methods 0.000 title abstract 3
- 238000003556 assay Methods 0.000 title abstract 2
- 230000037189 immune system physiology Effects 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000000427 antigen Substances 0.000 claims abstract description 11
- 102000036639 antigens Human genes 0.000 claims abstract description 10
- 108091007433 antigens Proteins 0.000 claims abstract description 10
- 230000001900 immune effect Effects 0.000 claims abstract description 10
- 239000012634 fragment Substances 0.000 claims abstract description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 6
- 230000009257 reactivity Effects 0.000 claims abstract description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000008569 process Effects 0.000 claims abstract description 4
- 239000011701 zinc Substances 0.000 claims abstract description 4
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 4
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 108091026813 Poly(ADPribose) Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000220259 Raphanus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- -1 amino- Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9307792A FR2707011A1 (en) | 1993-06-25 | 1993-06-25 | Immunological process for the detection and assay of antibodies directed against poly(ADP-ribose) polymerase, application to diagnosis, kit for its implementation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9307792A FR2707011A1 (en) | 1993-06-25 | 1993-06-25 | Immunological process for the detection and assay of antibodies directed against poly(ADP-ribose) polymerase, application to diagnosis, kit for its implementation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2707011A1 true FR2707011A1 (en) | 1994-12-30 |
| FR2707011B1 FR2707011B1 (enrdf_load_stackoverflow) | 1995-09-08 |
Family
ID=9448583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9307792A Granted FR2707011A1 (en) | 1993-06-25 | 1993-06-25 | Immunological process for the detection and assay of antibodies directed against poly(ADP-ribose) polymerase, application to diagnosis, kit for its implementation |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2707011A1 (enrdf_load_stackoverflow) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2782998A1 (fr) * | 1998-09-08 | 2000-03-10 | Inst Curie | Anticorps monoclonaux anti-proteine ozf et leurs applications dans le domaine diagnostic et therapeutique |
| WO2000023804A1 (fr) * | 1998-10-21 | 2000-04-27 | Centre National De La Recherche Scientifique | Procede de detection de l'activite enzymatique de l'enzyme poly(adp-ribose polymerase) |
| WO2000026192A1 (de) * | 1998-11-03 | 2000-05-11 | Basf Aktiengesellschaft | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| WO1999064572A3 (de) * | 1998-06-05 | 2000-06-08 | Basf Ag | Poly(adp-ribose) polymerase-gene |
| WO2000058518A3 (en) * | 1999-03-29 | 2001-12-20 | Cedars Sinai Medical Center | Genetic marker test for lupus |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018920A1 (fr) * | 1990-06-06 | 1991-12-12 | Neosystem S.A. | PEPTIDES DE L'ANTIGENE Sm-D ET LEUR UTILISATION NOTAMMENT POUR LE DIAGNOSTIC DU LUPUS ERYTHEMATEUX DISSEMINE |
| FR2682113A1 (fr) * | 1991-06-25 | 1993-04-09 | Centre Nat Rech Scient | Peptides issus de la proteine a de la ribonucleoproteine snrnp-u1 et leur utilisation pour le diagnostic de la connectivite mixte. |
-
1993
- 1993-06-25 FR FR9307792A patent/FR2707011A1/fr active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018920A1 (fr) * | 1990-06-06 | 1991-12-12 | Neosystem S.A. | PEPTIDES DE L'ANTIGENE Sm-D ET LEUR UTILISATION NOTAMMENT POUR LE DIAGNOSTIC DU LUPUS ERYTHEMATEUX DISSEMINE |
| FR2682113A1 (fr) * | 1991-06-25 | 1993-04-09 | Centre Nat Rech Scient | Peptides issus de la proteine a de la ribonucleoproteine snrnp-u1 et leur utilisation pour le diagnostic de la connectivite mixte. |
Non-Patent Citations (5)
| Title |
|---|
| BOULIKAS: "Poly(ADP-ribose) synthesis in blocked ....", ANTICANCER RESEARCH, vol. 12, 1992, ATHENS, pages 885 - 898 * |
| NEGRI ET AL.: "Autoantibodies to poly(adp-ribose)polymerase in autoimmune disease", AUTOIMMUNITY, vol. 6, 1990, LONDON, pages 203 - 209 * |
| UCHIDA ET AL.: "Nucleotide sequence of a full-lenght ....", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 148, no. 2, 29 October 1987 (1987-10-29), NEW YORK NY, pages 617 - 622 * |
| YAMANAKA ET AL.: "Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase ....", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 83, January 1989 (1989-01-01), NEW YORK, NY, pages 180 - 186 * |
| YAMANAKA ET AL.: "Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 80, no. 3, September 1987 (1987-09-01), NEW YORK, NY, pages 900 - 904 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999064572A3 (de) * | 1998-06-05 | 2000-06-08 | Basf Ag | Poly(adp-ribose) polymerase-gene |
| US7754459B1 (en) | 1998-06-05 | 2010-07-13 | Basf Aktiengesellschaft | Poly(ADP-ribose) polymerase-gene |
| US9051553B2 (en) | 1998-06-05 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Poly(ADP-ribose) polymerase genes |
| FR2782998A1 (fr) * | 1998-09-08 | 2000-03-10 | Inst Curie | Anticorps monoclonaux anti-proteine ozf et leurs applications dans le domaine diagnostic et therapeutique |
| WO2000023804A1 (fr) * | 1998-10-21 | 2000-04-27 | Centre National De La Recherche Scientifique | Procede de detection de l'activite enzymatique de l'enzyme poly(adp-ribose polymerase) |
| FR2785053A1 (fr) * | 1998-10-21 | 2000-04-28 | Centre Nat Rech Scient | Procede de detection de l'activite enzymatique de l'enzyme poly(adp-ribose polymerase) et de detection de l'activite inhibitrice ou activatrice d'un inhibiteur ou d'un activateur de cette enzyme |
| WO2000026192A1 (de) * | 1998-11-03 | 2000-05-11 | Basf Aktiengesellschaft | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| US7781596B1 (en) | 1998-11-03 | 2010-08-24 | Abbott Laboratories | Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| WO2000058518A3 (en) * | 1999-03-29 | 2001-12-20 | Cedars Sinai Medical Center | Genetic marker test for lupus |
| GB2366378B (en) * | 1999-03-29 | 2004-06-16 | Cedars Sinai Medical Center | Genetic marker test for lupus |
| US7037651B2 (en) | 1999-03-29 | 2006-05-02 | Cedars-Sinai Medical Center | Genetic marker test for lupus |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2707011B1 (enrdf_load_stackoverflow) | 1995-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wegner et al. | Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α‐enolase: implications for autoimmunity in rheumatoid arthritis | |
| Rosenstein et al. | Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis | |
| Lundberg et al. | Antibodies to citrullinated α‐enolase peptide 1 are specific for rheumatoid arthritis and cross‐react with bacterial enolase | |
| EP0423301B1 (fr) | Peptides synthetiques du conjugue de l'ubiquitine et de l'histone h2a | |
| FR2669929A1 (fr) | Composition d'antigenes, procede de detection de helicobacter pylori a l'aide de cette composition et necessaire la contenant. | |
| Baum et al. | The PBC-specific antigen | |
| US8323656B2 (en) | Antigen determinant of rheumatoid arthritis-specific autoantibody and use thereof | |
| EP0547164A1 (en) | Methods for the diagnosis and treatment of diabetes | |
| CA2199498A1 (en) | Method of detecting autoantibody present in the serum of rheumatic | |
| FR2707011A1 (en) | Immunological process for the detection and assay of antibodies directed against poly(ADP-ribose) polymerase, application to diagnosis, kit for its implementation | |
| FR2677653A1 (fr) | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune. | |
| CA2127550A1 (en) | Multifunctional surface protein of streptococci | |
| Reichlin et al. | Radioimmunoassay for human myoglobin. Initial experience in patients with coronary heart disease. | |
| EP0667897B1 (fr) | Methode d'immunodosage specifique de la glutathion peroxydase plasmatique humaine | |
| EP0491014B1 (fr) | PEPTIDES DE L'ANTIGENE Sm-D ET LEUR UTILISATION NOTAMMENT POUR LE DIAGNOSTIC DU LUPUS ERYTHEMATEUX DISSEMINE | |
| JP3425149B2 (ja) | 無症候性患者における糖尿病可能性評価方法 | |
| EP2252897A2 (fr) | Procede de detection directe de l'albumine modifiee de l'ischemie par utilisation d'un partenaire de liaison a un derive aldehyde issu de la peroxydation de lipides sous forme liee | |
| WO1999066332A1 (fr) | Procede et trousse de diagnostic precoce du cancer | |
| EP0495971B1 (fr) | Determination des thrombopenies | |
| US20050130241A1 (en) | Immunological detection of prostate diseases and prostasome-related conditions | |
| JP2744001B2 (ja) | 膵臓チモーゲンの遊離活性化ペプチドの免疫分析による診断、厳密な予測および監視 | |
| FR2682113A1 (fr) | Peptides issus de la proteine a de la ribonucleoproteine snrnp-u1 et leur utilisation pour le diagnostic de la connectivite mixte. | |
| EP0494825A1 (fr) | Peptides synthétiques dérivant de l'antigène HBc du virus de l'hépatite B | |
| JP5048205B2 (ja) | 精神分裂病の診断のための新規ペプチド | |
| FR2773078A1 (fr) | Utilisation de peptides citrullines derives de la filaggrine pour le traitement de la polyarthrite rhumatoide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse | ||
| ST | Notification of lapse |